First-in-Human Clinical Trial with Intratumoral PeptiCRAd-1 in Combination with Pembrolizumab: Assessment of Safety & Immunological MoA

Time: 6:15 pm
day: Track A - Day 1 pm


• PeptiCRAd technology combines OV and peptide vaccine providing a flexible therapeutic vaccine platform focused on generating cytotoxic T cell responses
• First-in-human clinical trial in combination with PeptiCRAd-1 and pembrolizumab starting early 2022
• Extensive immune monitoring planned for the assessment of MoA and biomarker identification